Welcome to our dedicated page for AEON Biopharma news (Ticker: AEON), a resource for investors and traders seeking the latest updates and insights on AEON Biopharma stock.
AEON Biopharma develops ABP-450 (prabotulinumtoxinA) as a proposed biosimilar to BOTOX (onabotulinumtoxinA) for therapeutic indications. Company announcements focus on analytical similarity work, FDA biosimilar pathway interactions, scientific presentations, and the regulatory strategy supporting ABP-450 development.
Recurring AEON updates also address operating and financial results, liquidity and going-concern disclosures, shareholder meeting matters, inducement equity awards, executive and governance changes, capital-structure actions, and NYSE American continued-listing compliance.
AEON Biopharma (AEON) reported positive pilot forced degradation results comparing its botulinum toxin candidate ABP-450 with BOTOX® under thermal and oxidative stress.
Both products showed comparable potency loss over 14 days of high-heat exposure, each declining to about half of initial observed potency, and displayed similar dose-dependent oxidation patterns at evaluated methionine sites. These findings add another analytical line of evidence for structural comparability and establish stress conditions for a planned multi-lot comparability study, which AEON expects to initiate in the first half of 2027 as part of the analytical package for a planned 351(k) BLA.
AEON Biopharma (NYSE American: AEON) announced that its management team will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference in New York City on Thursday, September 10, 2026. Interested investors should contact their Lake Street representative for invitations and scheduling.
AEON Biopharma (NYSE American: AEON) appointed Paul Lee, M.D., Ph.D., former Deputy Director of the FDA’s Office of Neuroscience, as acting Chief Regulatory Officer through Clintrex Research. Dr. Lee and Clintrex already advise AEON on regulatory and clinical strategy for ABP-450, a biosimilar to BOTOX for therapeutic use.
In his expanded role, Dr. Lee will lead AEON’s regulatory strategy, oversee FDA interactions and collaborate with analytical, CMC and clinical teams as ABP-450 advances under the 351(k) biosimilar pathway. He previously held senior roles within the FDA’s Office of New Drugs and co-authored a publication on Tyruko, the first FDA-approved biosimilar to natalizumab.
AEON (NYSE American: AEON) reported final, expanded primary structure results and preliminary disulfide bond data for ABP-450, its proposed biosimilar to BOTOX for therapeutic use. Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed.
According to AEON, preliminary disulfide characterization showed the same single interchain disulfide bond C430-C454 linking light and heavy chains in both ABP-450 and BOTOX across all tested lots, representing about 99% of total species. The FDA previously indicated AEON’s analytical similarity strategy under the 351(k) biosimilar pathway appeared reasonable, and the company expects additional BPD Type 2b feedback in the second half of 2026 to guide the next development phase.
AEON Biopharma (NYSE American: AEON) reported second quarter 2026 results and development progress for ABP-450, its proposed therapeutic biosimilar to BOTOX. The company highlighted a successful FDA Biosimilar Biological Product Development Type 2a meeting, where the FDA supported AEON’s analytical similarity strategy under the 351(k) pathway and provided a framework for remaining analytical work.
AEON completed a July 2026 underwritten public offering with $15.3 million in financing, yielding approximately $13.6 million in net upfront proceeds and milestone warrants that could provide up to $34.0 million in additional gross proceeds. Cash and cash equivalents were $3.4 million at June 30, 2026, excluding the July proceeds, which are expected to fund operations into the first quarter of 2027. The company also restored full NYSE American listing compliance and presented new analytical and structural comparability data for ABP-450 at major neurology and headache meetings.
For the three months ended June 30, 2026, AEON reported total operating expenses of $5.9 million and a net loss of $1.2 million, versus a net loss of $6.6 million a year earlier, with results impacted by fair value changes in warrants and convertible notes.
AEON Biopharma (NYSE American: AEON) announced it has regained compliance with NYSE American continued listing standards related to stockholders’ equity. NYSE Regulation confirmed that previously identified deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the Company Guide have been resolved, and AEON expects the “.BC” below-compliance indicator to be removed from its Class A common stock.
Compliance was regained after an underwritten public offering closed on July 15, 2026, including 17,851,599 shares of common stock and pre-funded warrants for 24,837,008 shares, plus 4,696,102 additional shares sold on July 23, 2026 via over-allotment. AEON received approximately $13.6 million in net proceeds and may receive up to $34.0 million more upon full cash exercise of milestone warrants, and believes its stockholders’ equity now exceeds the $4.0 million minimum requirement.
AEON Biopharma (NYSE American: AEON) priced an upsized underwritten public offering for expected gross proceeds of approximately $13.75 million, with potential total proceeds of up to about $43.3 million if all accompanying milestone warrants are exercised in cash.
The offering comprises 42,688,606 shares of common stock (or pre-funded warrants) at a combined public offering price of $0.3221 per share and two milestone warrants (or $0.3220 per pre-funded warrant package). Each package includes one two-year milestone warrant with a $0.3221 exercise price and one five-year milestone warrant with a $0.3704 exercise price, all immediately exercisable. AEON granted a 30-day over-allotment option for up to 6,403,290 additional shares and/or milestone warrants. Closing is expected on or about July 15, 2026, subject to customary conditions, and proceeds are intended for working capital and comparative analytical testing of ABP-450 to support its biosimilarity to BOTOX.
AEON Biopharma (NYSE American: AEON) is presenting new analytical and functional data on ABP-450 at the 68th American Headache Society meeting on June 4, 2026. The poster shows structural and functional comparability of ABP-450 to BOTOX using genomic alignment, LC-MS peptide mapping, and LD50 potency assays.
AEON Biopharma (NYSE American: AEON) reported Q1 2026 results and a corporate update. The FDA considered its ABP-450 analytical similarity strategy under the 351(k) biosimilar pathway reasonable, supporting advancement toward a comprehensive package.
AEON closed a $6 million PIPE and Daewoong note exchange, cutting debt by over 90%, named John Bencich CFO, reported $6.2 million cash on March 31, 2026, and expects funding into Q3 2026. Planned 2026 milestones include a BPD Type 2b FDA meeting.
AEON Biopharma (NYSE American: AEON) will hold its Annual Shareholder Meeting at 10:00 am PT on June 17, 2026 at the company offices, 5 Park Plaza, Suite 1750, Irvine, CA. Meeting materials are expected on or about April 29, 2026.
The company disclosed an audit going concern qualification for the fiscal year ended December 31, 2025, reflecting its liquidity position as of the audit date. The company expects cash and cash equivalents to fund operations into the third quarter of 2026.